Home

NADINA trial results support the use of neoadjuvant nivolumab plus ipilimumab, followed by response-driven adjuvant therapy, in patients with stage III melanoma.

Sleep and cardiovascular disease have a complex relationship. Is prevention of sleep disturbance a useful approach for tackling heart disease? 

Seralutinib delivered via inhaler significantly reduces pulmonary vascular resistance in patients with pulmonary arterial hypertension.

Salpingo-oophorectomy was performed after 15 years’ surveillance of an ovarian dermoid cyst in a female with type 2 diabetes. The removed ovary contained a mature cystic teratoma and a discrete solid nodule.

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

An expert-led symposium exploring the prevention and management of type 2 diabetes through dietary interventions. Highlights include discussion of the recent EASD guidelines, therapeutic diets, food types and processing, plus psychological factors that influence patient success, and the drivers of healthy eating and diabetes control.

An expert-led symposium exploring the most pertinent issues in cardio-oncology, with a focus on the new ESC guidelines. Highlights include preventative approaches in cardio-oncology, toxicity risk-stratification strategies, the clinical management of myocarditis as an adverse effect of immune checkpoint inhibitor-treatments, and the utility of biomarkers in long-term follow-up of cardiovascular disease risk in cancer patients.